definiens: means all Patent Rights Controlledby [COMPANY] or its Affiliates on the Execution Date or at any time during the Term Covering ( a ) thecomposition of matter of the Compound, intermediates or the Product, ( b ) methods of using theCompound, intermediates or the Product, or ( c ) an oligonucleotide compound that specificallymodulates expression of ANGPTL3 via the binding, partially or wholly, of such compound toRNA that encodes ANGPTL3 ; provided, however, that Patent Rights Controlled by [COMPANY] or anyof its Affiliates to the extent that such Patent Rights include any claims that are directed to ( i)subject matter applicable to oligonucleotide compounds or products in general or ( ii ) anoligonucleotide compound that does not specifically modulate expression of ANGPTL3 via thebinding, partially or wholly, of such compound to RNA that encodes ANGPTL3, will not beconsidered [COMPANY] Product - Specific Patent Rights . Patent Rights that would otherwise qualify asAkcea Product - Specific Patent Rights but for clauses ( i ) or ( ii ) will be considered [COMPANY] CoreTechnology Patent Rights . For clarity, [COMPANY] Product - Specific Patent Rights do not include anyPatent Rights claiming formulation technology or delivery devices ( other than ConjugateTechnology ) . The [COMPANY] Product - Specific Patent Rights as of the Execution Date are set forth onSchedule 1.18 attached hereto